transition from tirzepatide to retatrutide Switching and What You Should Know Before Making the Change Retatrutide vs Tirzepatide — Key
Description
Flint, A., Raben, A., Rehfeld, J
Tirzepatide Dual-action drug, targeting both glucose metabolism and appetite regulation
However, not all patients respond effectively to GLP-1R monoagonists, and higher doses aimed at increasing efficacy result in adverse gastrointestinal effects
The most realistic approval window is late 2027 to 2028
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
The pricing is competitive, especially on longer plans: $283/month for tirzepatide on the 12-month plan
